GlassScriptPhysician profile
Karen T Hacker
NPI 1942392758
$3,903.75
in general payments reported to CMS, 2019-2025
32 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $430 · 2021: $283 · 2022: $249 · 2023: $608 · 2024: $1,079 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $366.22 | 2019-2025 | |
| Abbvie INC. | $321.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $314.42 | 2023-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $264.90 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.15 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $225.03 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $203.93 | 2019-2024 | |
| Amgen INC. | $167.62 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $155.90 | 2019-2020 | |
| Astellas Pharma US INC | $155.36 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.16 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $90.10 | 2021 | |
| Abbott Laboratories | $76.89 | 2022-2025 | Eterna, Proclaim |
| Phathom Pharmaceuticals, INC. | $75.11 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $72.52 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $64.73 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $56.97 | 2023 | Spravato |
| Merck Sharp & Dohme LLC | $49.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $46.11 | 2019-2020 | |
| Esperion Therapeutics, INC. | $31.11 | 2020-2023 | Nexletol |
| Exact Sciences Corporation | $29.04 | 2023-2024 | Cologuard Collection Kit |
| Vifor Pharma, INC. | $23.88 | 2024 | Zemaira |
| Xeris Pharmaceuticals, INC. | $20.67 | 2024 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $19.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2021 | |
| Mylan Specialty L.P. | $15.95 | 2020 | |
| Kaleo, INC. | $15.34 | 2020 | |
| Medtronic USA, INC. | $13.93 | 2019 | |
| Dexcom, INC. | $13.76 | 2023 | Dexcom G6 Transmitter |
| Shire North American Group INC | $13.45 | 2019 | |
| Phadia US INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Hacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.